12 - AmerisourceBergen

/Users/clayhayner/Desktop/ICSDC_ABSG_110609/ABSG_ICS_Warehouse_TIF/.ABSG_ISC_Warehouse__255.tif - Courtesy of AmerisourceBergen
/Users/clayhayner/Desktop/ICSDC_ABSG_110609/ABSG_ICS_Warehouse_TIF/.ABSG_ISC_Warehouse__255.tif Courtesy of AmerisourceBergen

The Pennsylvania-based drug distributor saw revenues grow in 2017 thanks to increased business from some of its largest customers and strong sales of expensive cancer drugs. Amerisources’s animal health unit, MWI, also recorded strong sales growth thanks to its brisk pet medicine business. Profits took a hit due to accrued litigation costs from the previous year. Like other large drug distributors, Amerisource faces a number of lawsuits over its alleged role in the nation’s opioid epidemic.

More from FORTUNE

Key Metrics & Financials (Last Fiscal Year)

Previous Rank11
Revenues ($M)$153144
Revenue Percent Change4.3%
Profits ($M)$364.5
Profits Percent Change-74.5%
Assets ($M)$35317
Market Value — as of March 29, 2018 ($M)$18938

Company Facts

IndustryWholesalers: Health Care
HQ LocationChesterbrook, Pa.
CEOSteven H. Collis
CEO Title-
Years on Fortune 500 List24

See Full List


More from FORTUNE